U.S. Markets open in 7 hrs 36 mins

NanoViricides, Inc. (NNVC)

NYSE MKT - Nasdaq Real Time Price. Currency in USD
Add to watchlist
1.50+0.02 (+1.35%)
At close: 3:59PM EDT
People also watch
BTXISCOGALTAVXLECTE
Full screen
Previous Close1.48
Open1.49
Bid0.00 x
Ask0.00 x
Day's Range1.49 - 1.55
52 Week Range1.03 - 1.80
Volume107,986
Avg. Volume102,358
Market Cap94.61M
Beta0.11
PE Ratio (TTM)-9.38
EPS (TTM)-0.16
Earnings DateMay 12, 2017 - May 15, 2017
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.30
Trade prices are not sourced from all markets
  • NanoViricides Reports Its Drug Candidates Significantly Reduced the Extent of Shingles Virus Infection of Human Skin
    PR Newswire17 days ago

    NanoViricides Reports Its Drug Candidates Significantly Reduced the Extent of Shingles Virus Infection of Human Skin

    SHELTON, Conn., July 10, 2017 /PRNewswire/ -- NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company") reports that its anti-shingles nanoviricides® drug candidates achieved dramatic reduction in infection of human skin by the varicella-zoster virus (VZV), the shingles virus. The antiviral effect of certain nanoviricide drug candidates was substantially greater than the effect of the standard positive control of cidofovir added into media.

  • NanoViricides' Poster "Novel Nanoviricides® Highly Effective Against Varicella Zoster Virus in Cell Culture" to be Presented Today at the 2017 Annual Meeting of American Society of Virology
    PR Newswirelast month

    NanoViricides' Poster "Novel Nanoviricides® Highly Effective Against Varicella Zoster Virus in Cell Culture" to be Presented Today at the 2017 Annual Meeting of American Society of Virology

    SHELTON, Conn., June 26, 2017 /PRNewswire/ -- NanoViricides, Inc., (NYSE MKT: NNVC) (the "Company"), a pioneer in developing anti-viral nanomedicine drugs, is pleased to announce that its poster entitled "Novel Nanoviricides® Highly Effective Against Varicella Zoster Virus in Cell Culture" will be presented today at the 36th Annual Meeting of the American Society of Virology (ASV). Dr. Brian Friedrich, Senior Virologist of the Company, is presenting the Company's work on the evaluation of nanoviricides drug candidates for effectiveness against the shingles virus (Varicella Zoster Virus, VZV, aka Human HerpesVirus-3 or HHV-3) in this poster.

  • NanoViricides Abstract Accepted for Poster Presentation at the 2017 Annual Meeting of American Society of Virology
    PR Newswirelast month

    NanoViricides Abstract Accepted for Poster Presentation at the 2017 Annual Meeting of American Society of Virology

    SHELTON, Conn., June 20, 2017 /PRNewswire/ -- NanoViricides, Inc., (NYSE MKT: NNVC) (the "Company"), a pioneer in developing anti-viral nanomedicine drugs, is pleased to announce that its late-breaking abstract submission has been accepted for a poster presentation at the 36th Annual Meeting of the American Society of Virology (ASV). The ASV Meeting will be hosted and held at the University of Wisconsin-Madison, from June 24th to 28th, 2017 (https://extensionconferencecenters.uwex.edu/asv2017/). Dr. Brian Friedrich, Senior Virologist of the Company, will present the Company's work on the evaluation of nanoviricides drug candidates for effectiveness against the shingles virus (Varicella Zoster Virus, VZV, aka Human HerpesVirus-3 or HHV-3).